We reviewed the licensed antifungal drugs and summarized their mechanisms of action,
pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1 …

Clinically available antifungals for the treatment of invasive fungal infections primarily target
either ergosterol in the fungal cell membrane or 1, 3-β-D-glucan in the fungal cell wall …

Serious fungal infections, caused mostly by opportunistic species, are increasingly common
in immunocompromised and other vulnerable patients. The use of antifungal drugs, primarily …

Due to their eukaryotic heritage, the differences between a fungal pathogen's molecular
makeup and its human host are small. Therefore, the discovery and subsequent …

Fungal infections represent an increasing threat to a growing number of immune-and
medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a …

Antifungal resistance represents a major clinical challenge to clinicians responsible for
treating invasive fungal infections due to the limited arsenal of systemically available …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

Fungal infections are a universal problem and are routinely associated with high morbidity
and mortality rates in immunocompromised patients. Existing therapies comprise five …

The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles)
in the past decade has transformed the management of invasive mycoses to the point that …

Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to healthcare …